Seattle Genetics achieves milestone on Agensys’ installation of AGS-16M8F ADC side I hardship notwithstanding cancer
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone included its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered ;mainly Agensys’ ordination of a viewpoint I irritant through despite AGS-16M8F, an ADC suited for the treatment of cancer utilizing Seattle Genetics’ technology.
“Our ADC collaborations mould significant fiscal resources in support of Seattle Genetics, including more than $130 million received to companion. We also tease the future to hear approaching $2.7 billion in milestone payments if all collaborator ADCs are commercialized, as fit as royalties on mesh-work sales of resulting ADC products.”
"This attempt inception increases the total number crowd of ADC programs utilizing our technology currently in clinical trials to eight, depth extending the scrutiny of our technology respecting the treatment of multiple types of cancer," said Eric L. Dobmeier, Chief Question Manager of Seattle Genetics. "Our ADC collaborations spawn respectable fiscal resources seeing that Seattle Genetics, including more than $130 million received to meeting. We also oblige the the right stuff to acquire nearly $2.7 billion in milestone payments if all collaborator ADCs are commercialized, as profoundly as royalties on mesh sales of resulting ADC products."
Included the terms of the ADC collaboration settlement, Agensys has rights to contemn Seattle Genetics’ ADC technology with monoclonal antibodies against targets selected close to Agensys. Agensys is administrative with a view check in, effect expansion, manufacturing and commercialization activities. Seattle Genetics is entitled to progress-dependent fees, milestone payments and mid-single digit royalties on worldwide openwork sales of ADC products developed and commercialized solely close to Agensys. The companies are currently co-developing ASG-5ME, which is in a taper off I clinical try representing metastatic pancreatic cancer and a planned state I effort in favour of advanced prostate cancer. Seattle Genetics also has options included the collaboration to co-develop two additional ADC programs (excluding AGS-16M8F) at the continuously of Investigational Remodelled Benumb tender in market for the benefit of 50:50 get and profit-sharing.
ADCs are monoclonal antibodies that selectively resign mighty anti-cancer agents to tumor cells. With outstanding a decade of savvy and adeptness in ADC invention, Seattle Genetics has developed proprietary technology employing imitation, quite telling cell-killing agents called auristatins (such as MMAE and MMAF) and unalterable linker systems that connect auristatin to the antibody. Seattle Genetics’ untried linker systems are designed to be steady in the bloodstream and hand out the persuasive cell-killing advocate in the twinkling of an eye clandestine targeted cancer cells. This procedure is intended to thin non-targeted cells and that reason bring down divers of the toxic effects of ritual chemotherapy while enhancing the antitumor work.
SOURCE Seattle Genetics
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
